Clinical Trial Update: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) [Phase 1, Phase 2]

View source ↗

Summary

KL264-01, a Trop2-targeted antibody-drug conjugate, is being studied in a Phase 1/2 trial for advanced unresectable or metastatic solid tumors refractory to sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Epithelial Ovarian Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• KL264-01

Snippet

Sponsor: Klus Pharma Inc. | Conditions: Epithelial Ovarian Cancer, Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING